Provided are a recombinant oncolytic virus and a use thereof. The recombinant oncolytic virus includes an M protein and an antigen encoded by an exogenous gene, wherein the M protein includes the following site mutations compared to an amino acid sequence as shown in SEQ ID NO 1: mutating of methionine at position 51 into arginine (M51R); mutating of valine at position 221 into phenylalanine (V221F); and mutating of serine at position 226 into arginine (S226R). The recombinant oncolytic viruses provided have better infective ability and killing ability in vitro to abnormally proliferative (tumor) LLC cell and are all not easy to eliminate in the LLC cell, greatly reducing the infective ability of the recombinant oncolytic viruses to normal cells.
The present application relates to the technical field of biomedicine, and in particular to a method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug. Specifically, the method comprises the following steps: treating a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug, wherein the small-molecule anticancer drug includes a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4/6, and a small-molecule anticancer drug targeting KRAS; and the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein after site-directed mutagenesis. According to the present application, the recombinant oncolytic virus and the small-molecule anticancer drug are used in combination to attack and kill tumor cells, thereby achieving the synergistic efficacy.
The present application discloses an oncolytic virus and a use thereof. The oncolytic virus comprises an M protein, in which the M protein includes amino acid substitution(s) at one or more of the following positions compared to an amino acid sequence set forth in SEQ ID NO 1: position 32, position 33, position 49, position 54, position 133, and position 225. Further disclosed are an expression vector for the oncolytic virus, a virus production cell capable of producing the oncolytic virus, and a pharmaceutical composition including the oncolytic virus, as well as a method for preparing the oncolytic virus, the expression vector for the oncolytic virus, the virus production cell, and/or the pharmaceutical composition, and a use of the oncolytic virus, the expression vector for the oncolytic virus, the virus production cell, and/or the pharmaceutical composition.
The invention relates to the technical field of biomedicine, and specifically to a method for treating tumors using a combination of an oncolytic virus vaccine and immune cells. The method specifically comprises the following steps: treating a tumor by using a combination of immune cells and an oncolytic virus vaccine; the oncolytic virus vaccine comprising a recombinant oncolytic virus expressing a tumor antigen, and used for targeting tumor cells; the immune cells are embedded in an antigen receptor paired with the tumor antigen, and are used for killing or destroying tumor cells of a target; and the recombinant oncolytic virus comprises an M protein, G protein, N protein, P protein, and L protein, following site-directed mutagenesis. The combination of the oncolytic virus vaccine and the immune cells for killing or destroying the tumor antigen is used for attacking and killing tumor cells, and the tumor antigen expressed by the oncolytic virus vaccine can not only guide the immune cells to reach the center of a target tumor tissue, but the combination of the oncolytic virus and immune cells to kill tumor cells achieves a curative effect where 1+1 is greater than 2, with a maximum tumor cell killing rate being able to reach 100%.
The present disclosure provides methods of treating cancer using complementary transgenic oncolytic viruses and genetically engineered CAR T cells. In one embodiment, the oncolytic virus comprises nucleotide sequences encoding CD19, or CD19 and IL-12, and the genetically engineered T cells express a chimeric antigen receptor that recognizes CD19.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided is an oncolytic virus, including an M protein and a G protein. The M protein includes amino acid substitutions at positions 51, 221, and 226 compared with an amino acid sequence as shown in SEQ ID NO: 1. The G protein includes at least one amino acid substitution compared with an amino acid sequence as shown in SEQ ID NO: 2. Further provided are an expression vector of the oncolytic virus, a virus production cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus, and a method for preparing the oncolytic virus, the expression vector of the oncolytic virus, the virus production cell, and/or the pharmaceutical composition, and an use thereof.
Provided are a recombinant oncolytic virus and the use thereof. The recombinant oncolytic virus comprises an M protein and a cytokine encoded by an exogenous gene. Compared with the amino acid sequence as shown in SEQ ID NO. 1, the M protein comprises the following site mutations: methionine at position 51 is mutated into arginine (M51R); valine at position 221 is mutated into phenylalanine (V221F); and serine at position 226 is mutated into arginine (S226R). The provided recombinant oncolytic virus has a good infection ability and in-vitro killing ability on dysproliferative (tumor) LLC cells, 4T1 cells, MC38 cells and Hela cells, and is not easy to clear from LLC cells, 4T1 cells, MC38 cells, and Hela cells, thereby having a greatly reduced infection ability on normal cells.
Provided are a recombinant oncolytic virus and the use thereof. The recombinant oncolytic virus comprises an M protein and an antigen encoded by an exogenous gene. Compared with the amino acid sequence represented by SEQ ID NO 1, the M protein comprises the following site mutations: the methionine at the 51st site being mutated into arginine (M51R); the valine at the 221st site being mutated into phenylalanine (V221F); and the serine at the 226th site being mutated into arginine (S226R). The provided recombinant oncolytic virus has good infection capability and in-vitro killing capability on abnormally proliferative (tumor) LLC cells and is not liable to be eliminated in LLC cells, and has greatly attenuated infection capability on normal cells.
The present application relates to an attenuated oncolytic virus strain, an oncolytic virus vaccine and a drug for treating tumors by combining the oncolytic virus vaccine with immune cells. The present application provides a new attenuated oncolytic virus strain by a site-directed mutation of a matrix protein M of a VSV wild-type virus. On the basis of the attenuated oncolytic virus strain, the present application further provides a vaccine that can be used in tumor treatment. On the basis of the vaccine, the present application further provide a drug that can effectively treat multiple kinds of tumors by combining the vaccine with immune cells.
The present application relates to the technical field of biomedicine, and specifically discloses an oncolytic virus and the use thereof. The oncolytic virus comprises an M protein, and the M protein contains amino acid substitutions at one or more of the following sites: 32nd, 33rd, 49th, 54th, 133rd and 225th sites in comparison with the amino acid sequence shown in SEQ ID NO: 1. Further disclosed in the present application are an expression vector for the oncolytic virus, a virus-producing cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus; and a method for preparing the oncolytic virus, the expression vector for the oncolytic virus, the virus-producing cell and/or the pharmaceutical composition and the use. The present application can effectively improve the safety and cure rate of the oncolytic virus.
The present application relates to a medicine for treating tumors. A novel attenuated oncolytic virus strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the attenuated oncolytic virus strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.
Provided is an oncolytic virus, including an M protein and a G protein. The M protein includes amino acid substitutions at positions 51, 221, and 226 compared with an amino acid sequence as shown in SEQ ID NO: 1. The G protein includes at least one amino acid substitution compared with an amino acid sequence as shown in SEQ ID NO: 2. Further provided are an expression vector of the oncolytic virus, a virus production cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus, and a method for preparing the oncolytic virus, the expression vector of the oncolytic virus, the virus production cell, and/or the pharmaceutical composition, and an use thereof.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Provided is an oncolytic virus, comprising an M protein and a G protein. The M protein comprises amino acid substitutions at sites 51, 221, and 226 compared with the amino acid sequence as shown in SEQ ID NO: 1. The G protein comprises at least one amino acid substitution compared with the amino acid sequence as shown in SEQ ID NO: 2. Also provided are an oncolytic virus expression vector, a virus production cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus, and a preparation method for the oncolytic virus, the oncolytic virus expression vector, the virus production cell, and/or the pharmaceutical composition, and the use thereof.
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Combination of an oncolytic virus and modified immune effector cells for treatment of tumors. Provided are a composition comprising the oncolytic virus and the modified immune effector cells, a pharmaceutical composition, and a kit. Also provided are a preparation method for the composition, the pharmaceutical composition, and the kit, as well as a use of the composition, the pharmaceutical composition, and the kit in treatment of tumors and preparation of medications for treating tumors.
Provided are an oncolytic virus attenuated strain, an oncolytic virus vaccine and a drug for treating tumors by combining the oncolytic virus vaccine with immune cells. Provided is a new oncolytic virus attenuated strain, which is obtained by means of the site-directed mutation of a VSV wild-type virus matrix protein M. Also provided is a vaccine capable of being applied to tumor treatment on the basis of the oncolytic virus attenuated strain. Further provided is a drug capable of efficiently treating various tumors by means of applying the vaccine and immune cells in combination on the basis of the vaccine.
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
The present application relates to a medicine for treating tumors. A novel oncolytic virus attenuated strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the oncolytic virus attenuated strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.
The present application relates to a medicine for treating tumors. A novel oncolytic virus attenuated strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the oncolytic virus attenuated strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.
brevets
